Invivyd Announces Initiation Of DECLARATION Phase 3 Pivotal Clinical Trial Of Vaccine-Alternative Antibody VYD2311 To Prevent COVID, With Top-Line Data Expected Mid-2026

Benzinga · 3d ago
  • Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter
  • Preliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025
  • Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025
  • Potential best-in-class RSV antibody VBY329 nominated for preclinical development
  • Preclinical measles mAb candidate selection targeted for 1H 2026 for treatment and prevention of measles
  • Further updates to be provided in conjunction with Form 10-K filing and upcoming ordinary quarterly reporting